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Abstract Apoptotic protease activating factor-1 (Apaf-1) and
cytochrome c are cofactors critical for inducing caspase-9
activation following stress-induced apoptosis. One consequence
of caspase-9 activation is nuclear^cytoplasmic barrier disas-
sembly, which is required for nuclear caspase-3 translocation. In
the nucleus, caspase-3 triggers proteolysis of the caspase-
activated DNA nuclease (CAD) inhibitor, causing CAD
induction and subsequent DNA degradation. Here we demon-
strate that apoptotic cells show perinuclear cytochrome c
aggregation, which may be critical for nuclear redistribution
of cytochrome c and Apaf-1. We thus indicate that the nuclear
redistribution of these cofactors concurs with the previously
reported caspase-9-induced nuclear disassembly, and may
represent an early apoptotic hallmark. ß 2002 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
The execution mechanism of stress-induced apoptosis is
mediated by a group of proteases known as caspases (cystein-
yl aspartate-speci¢c proteinases) [1], which carry out the ap-
optotic program through a sequential activation cascade of
initiator and executioner caspases [2]. Apaf-1 (apoptotic pro-
tease activating factor-1) is a cofactor that induces activation
of initiator caspase-9 [3,4]. Apaf-1 binds caspase-9 via the
caspase recruitment domains at their NH2 termini, triggering
the formation of a supramolecular complex called the apo-
ptosome [3,4]. When activated, initiator caspase-9 triggers
subsequent proteolytic activation of executioner caspase-3 [3].
During stress-induced apoptosis, caspase activation also re-
quires a large number of post-translational mechanisms, in-
cluding translocation to other organelles [5] ; an example of
these mechanisms is caspase-9 translocation to the nucleus
[6,7]. In the nucleus, caspase-9 has been implicated in nu-
clear^cytoplasmic barrier disassembly, allowing an increase
in the di¡usion limit of nuclear pores [8]. This process induces
caspase-3 to enter the nucleus by di¡usion [8], where it trig-
gers caspase-activated DNA nuclease by proteolysis of its in-
hibitor, causing DNA degradation [9,10].
Since caspase-9 redistributes from cytosolic compartments
to the nucleus during stress-induced apoptosis, and caspase-9
activation requires Apaf-1 to form an active holoenzyme [11],
we studied whether this cofactor also redistributes to the nu-
cleus during apoptosis. Here we demonstrate that apoptotic
cells show perinuclear cytochrome c aggregation as well as
apparent Apaf-1 redistribution to the nucleus after stress-in-
duced apoptosis. Taken together, these results corroborate
previous reports showing caspase-9 translocation to the nu-
cleus and indicate that, during stress-induced apoptosis,
Apaf-1 appears to translocate from cytoplasmic organelles
to the rest of the cell, including the nucleus. This redistribu-
tion may be required to allow the increase in the local Apaf-1
concentration necessary for caspase-9 triggering of nuclear^
cytoplasmic barrier disassembly.
2. Materials and methods
2.1. Cell culture
NIH-3T3 ¢broblasts and HeLa cells were cultured in Dulbecco’s
modi¢ed Eagle’s medium supplemented with 10% heat-inactivated
fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 Wg/ml
streptomycin, 10 mM HEPES and 50 WM 2-mercaptoethanol (Sigma,
St. Louis, MO, USA), and maintained at 37‡C in a humidi¢ed 5%
CO2 atmosphere.
2.2. Antibodies and reagents
Anti-active caspase-3 antibody was purchased from Promega (Mad-
ison, WI, USA), human anti-mitochondrial antibody was used as
described [12], and monoclonal anti-cytochrome c antibody was
from Pharmingen (San Diego, CA, USA). Mouse anti-L-tubulin
(clone tub 2.1), actinomycin D and cisplatin were from Sigma. Rabbit
anti-Apaf-1 antibody was used as described [13].
2.3. Immuno£uorescence and image acquisition
For immuno£uorescence, cells were cultured in chamber slides,
washed in phosphate-bu¡ered saline (PBS), ¢xed in 4% paraformal-
dehyde (15 min, room temperature), pre-incubated in 2% bovine se-
rum albumin (BSA), and incubated for 1 h with primary antibody in
PBS containing 0.5% BSA and 0.1% Triton X-100. Cells were washed
three times in the same bu¡er and incubated for 1 h with Cy2-, Cy3-
or Cy5-conjugated secondary antibodies (Jackson ImmunoResearch,
West Grove, PA, USA). After washing, samples were incubated with
TOPRO-3 (Molecular Probes, Eugene, OR, USA) in PBS for DNA
staining. Serial Z-sections were obtained with an Ar^Kr laser and a
TCS-NT Leica confocal imaging system equipped with a 63U1.4 oil
PLAPO objective. Cy2 was analyzed at 488 nm, Cy3 at 568 nm, and
Cy5/TOPRO-3 at 647 nm. Images for each channel were captured
separately and assembled into a single ¢le with TCSMERGE software
(Leica Microsystems, Heidelberg, Germany) prior to analysis. All
confocal images were analyzed using the Leica Vista+ (Beta Release
2) program. Images were processed digitally using Adobe Photoshop
(Adobe Systems, San Jose, CA, USA).
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Fig. 1. Nuclear caspase-3 activation during stress-induced apoptosis. A: Untreated control NIH-3T3 ¢broblasts. NIH-3T3 ¢broblasts were cul-
tured and ¢xed as described (Section 2), then incubated with mouse anti-cytochrome c and human anti-mitochondrial antibodies (Section 2);
Cy2-conjugated anti-mouse (green) and Cy5 anti-human secondary antibodies (blue) were used. B: Actinomycin D-treated NIH-3T3 ¢broblasts
(5 Wg/ml, 12 h) were ¢xed and stained as above. C: NIH-3T3 ¢broblasts as in B were pretreated as before, then incubated with rabbit anti-ac-
tive caspase-3 antibody; Cy2-conjugated anti-rabbit secondary antibody (green) was used. Samples were washed, incubated with TOPRO-3
(blue) in PBS, then analyzed by confocal microscopy (Section 2).
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2.4. Measurement of caspase-9 activity
Cytosolic protein (20 Wg) was diluted ¢ve-fold in caspase bu¡er (25
mM HEPES pH 7.5, 0.1% CHAPS, 10% sucrose, 10 mM dithiothrei-
tol and 0.1 mg/ml ovalbumin) and incubated (1 h, 37‡C), with the
£uorescent substrate Ac-LEHD-AMC (acetyl-Leu-Glu-His-Asp-7-
amino-4-methylcoumarin; 10 mM); reactions were terminated by
adding HPLC bu¡er (water/acetonitrile 75/25, 0.1% tri£uoroacetic
acid). Cleaved substrate £uorescence was determined by C18 reverse
phase HPLC using £uorescence detection (338 nm excitation, 455 nm
emission). Control experiments con¢rmed linearity of substrate release
with time and protein concentration.
3. Results and discussion
Caspase-9 triggers nuclear^cytoplasmic barrier disassembly,
causing caspase-3 to enter the nucleus by di¡usion [8]. Ac-
cording to this model, active caspase-3 is localized in the
nucleus during apoptosis. To validate this hypothesis, we
treated NIH-3T3 cells with actinomycin D, which causes
stress-induced apoptosis, including cytochrome c release
from mitochondria and caspase-9 activation [14]. We analyzed
whether cytochrome c redistributes during actinomycin D-in-
duced apoptosis in NIH-3T3 cells. Co-localization analysis in
healthy NIH-3T3 cells showed cytochrome c in mitochondria
(Fig. 1A); in apoptotic NIH-3T3 cells, however, there was
striking perinuclear mitochondrial aggregation, as well as cy-
tochrome c redistribution to the nucleus (Fig. 1B). These data
indicate that cytochrome c is released from mitochondria dur-
ing actinomycin D-induced apoptosis. Moreover, we studied
the localization of active caspase-3 during actinomycin D-in-
duced apoptosis using an anti-caspase-3 antibody that specif-
ically stains active caspase-3 in apoptotic cells. Analysis of
actinomycin D-treated NIH-3T3 cells showed active caspase-3
localization in nuclei (Fig. 1C), con¢rming nuclear caspase-3
localization in apoptotic cells and thus validating the model.
Caspase-9 activation requires the cofactor Apaf-1 to form
an active holoenzyme [11]. We analyzed whether, during apo-
ptosis, Apaf-1 undergoes subcellular redistribution, which may
be required for caspase-9-induced nuclear^cytoplasmic barrier
disassembly. Caspase activation induces cytoskeletal collapse
during apoptosis ; this process is due to the degradation of
multiple structural proteins associated with the cytoskeletal
network [15]. To study whether Apaf-1 redistributes to the
nucleus during apoptosis, we used cytoskeletal collapse as an
indicator of actinomycin D-induced apoptosis. Cytoskeletal
collapse is detected during apoptosis using the L-tubulin mi-
crotubule marker. Confocal microscopy analysis of Apaf-1
and L-tubulin in untreated cells indicated that Apaf-1 did
not co-localize with the microtubule network (Fig. 2A).
Apaf-1 and L-tubulin localization was analyzed by immuno-
staining after 12 h of actinomycin D treatment. In actinomycin
D-treated cells, both a marked collapse in the microtubule
network and cell shrinkage were observed (Fig. 2B). We also
detected Apaf-1 in the nucleus of apoptotic cells, indicating
apparent Apaf-1 redistribution during actinomycin D-induced
apoptosis (Fig. 2B). These data suggest that, during stress-
induced apoptosis, Apaf-1 translocates from cytoplasmic or-
ganelles to the rest of the cell, including the nucleus.
To test whether Apaf-1 and cytochrome c accumulated
within the nucleus or were adsorbed to the nuclear envelope
early in apoptosis, we studied Apaf-1 and cytochrome c redis-
tribution in HeLa cells at di¡erent times after cisplatin treat-
ment. We found that cytochrome c redistributes 4 h after
cisplatin treatment, forming a ring structure (Fig. 3A,B). In
addition, we detected a di¡use cytochrome c pattern in the
nucleus at 8 h (Fig. 3C), a time point at which more than 60%
of cells are clearly apoptotic (not shown). These data indicate
that the cytochrome c release process may have two stages; in
Fig. 2. Cytoskeletal collapse and nuclear redistribution of Apaf-1
during stress-induced apoptosis. A: Untreated NIH-3T3 ¢broblasts
were pretreated as in Fig. 1, then incubated (1 h) with rabbit anti-
Apaf-1 (green) and mouse anti-L-tubulin (red). After incubation,
samples were washed, then incubated (1 h) in Cy2 anti-rabbit and
Cy3 anti-mouse antibodies. After washing, samples were analyzed
and serial Z-sections obtained as above. B: Cells were actinomycin
D-treated for 12 h, then processed as above. The data are represen-
tative of the total cell population.
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the ¢rst, cytochrome c would move to the nuclear envelope, in
the second, it would be redistributed within the nucleus.
Apaf-1 is nonetheless detected inside the nucleus as early as
4 h after cisplatin treatment, a time at which cytochrome c
does not show nuclear localization.
We next analyzed whether Apaf-1 and cytochrome c redis-
tribution is associated with caspase-9 activation. NIH-3T3
cells were cisplatin-treated at several time points, after which
Apaf-1 and cytochrome c localization were analyzed by im-
munostaining; caspase-9 activity was measured in parallel.
We found caspase-9 activity as well as Apaf-1 redistribution
at a time at which cytochrome c did not show nuclear local-
ization, suggesting that caspase-9 activation and Apaf-1 trans-
location occur earlier than this characteristic pattern of cyto-
chrome c release (Fig. 4A,B).
A growing number of studies suggest that relocalization
and aggregation of apoptotic signaling proteins are important
steps in caspase activation. Apaf-1 triggers its apoptotic e¡ect
by oligomerization and subsequent activation of caspase-9
[16]. The fact that Apaf-1 is a transcriptional target of p53
also indicates that the cellular concentration of Apaf-1 is an
important molecular determinant of the stress-induced apo-
ptosis threshold [17^19]. In this study, we show apparent sub-
cellular redistribution of Apaf-1, which may be required to
allow the increase of the local Apaf-1 concentration necessary
for caspase-9 triggering of nuclear^cytoplasmic barrier disas-
sembly. Further studies are needed, however, to determine
whether the relationship described here between Apaf-1 sub-
cellular redistribution and stress-induced apoptosis has a role
in in vivo caspase-9 activation.
Fig. 3. Apaf-1 redistributes earlier than cytochrome c. A: Untreated HeLa cells. B: Cisplatin-treated HeLa cells (10 Wg/ml, 4 h). C: Cisplatin-
treated HeLa cells (10 Wg/ml, 8 h). After treatment, cells were ¢xed and pretreated as in Fig. 1, then incubated (1 h) with rabbit anti-Apaf-1
(red) and mouse anti-cytochrome c antibodies (green). After washing, samples were incubated (1 h) in Cy3 anti-rabbit and Cy2 anti-mouse anti-
bodies, and analyzed as before.
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In the nematode Caenorhabditis elegans, the CED-4 protein
(the Apaf-1 homologue) triggers activation of CED-3 (caspase
homologue) following CED-4 nuclear redistribution [20]. This
phenomenon is observed here in mammalian cells, suggesting
the conservation of this Apaf-1 function throughout evolu-
tion.
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